Explore the latest developments concerning This Company Now.
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
Eli Lilly just struck a major deal with the world's largest retailer.
Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became the world's best-selling drug in the third quarter. With year-to-date sales of $24.8 billion, it surpassed Keytruda, a blockbuster cancer immunotherapy drug made by pharmaceutical giant Merck.
Considering the stunning achievement, is this a good time to invest $1,000 into Eli Lilly? Let's take a closer look.
Third-quarter sales of Mounjaro and Zepbound combined were $10.1 billion, more than double the $4.4 billion they brought in during the third quarter of 2024. (Keytruda sales were $8.1 billion in the third quarter.) Sales of Mounjaro rose 109% in the quarter, while Zepbound sales rocketed 184% higher.
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
Eli Lilly (LLY +0.32%) has reported an impressive performance for the third quarter, with both revenues and earnings handily beating analysts' consensus estimates. Revenues rose 54% year over year to $17.6 billion, while adjusted earnings per share (EPS) soared by 495% to nearly $7.02. Management is now guiding for revenues of $63 billion to $65 billion in 2025, up from its prior estimated range of $60 billion to $62 billion. The company also expects 2025's adjusted EPS to be in the range of $23 to $23.70, a significant improvement from the previous projection of $21.70 to $23.
Waterproof Outdoor Solar Power Bank 38800mAh Dual USB Travel Outdoor Solar Mobile Phone Charger Solar Powerbanks For Camping
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Take a break from the news and try our new weekly crossword.
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly.
Lilly’s tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, saw $10.1 billion in sales in the third quarter, the pharma giant said Thursday, bringing year-to-date sales of the product to $24.8 billion.
Merck, meanwhile, reported that Keytruda, a cancer immunotherapy, earned $8.1 billion in the third quarter, bringing year-to-date sales to $23.3 billion.
0 Comments